The aim of this registry-based retrospective study was to analyze the outcome of second allogeneic hematopoietic SCT (alloHSCT_2) performed in patients with lymphoma who had relapsed after a first allogeneic transplant (alloHSCT_1). Patients ⩾ 18 years who had received an alloHSCT_2 for lymphoma relapse between 2000 and 2011 were eligible. One hundred and forty patients were identified. The diagnosis was Hodgkin lymphoma (HL) in 31%, diffuse large B-cell lymphoma in 14%, T-cell lymphoma in 12%, indolent lymphoma in 19%, mantle cell lymphoma in 16% and other lymphomas in 8% of the patients. The median interval from alloHSCT_1 to alloHSCT_2 was 19 (range 4-116) months. Disease status at alloHSCT_2 was chemosensitive in 46%, refractory in 43% and unknown in 11% of the patients. Three-year PFS, OS, relapse incidence and nonrelapse mortality were 19%, 29%, 58% and 23%, respectively. PFS and OS were significantly affected by refractory disease at alloHSCT_2 and a short interval between alloHSCT_1 and alloHSCT_2. Long-term PFS was observed across all lymphoma subsets except for aggressive B-cell lymphoma. In conclusion, alloHSCT_2 is feasible and can result in long-term disease control in patients with lymphoma recurrence after alloHSCT_1, in particular if relapse occurs late and is chemosensitive.
INTRODUCTION
Allogeneic hematopoietic SCT (alloHSCT) has been shown to be an effective treatment option for selected patients with lymphoma who fail standard treatment including autologous HSCT (autoHSCT). [1] [2] [3] [4] [5] [6] [7] Accordingly, the number of lymphoma allotransplants registered with the European Society for Blood and Marrow Transplantation (EBMT) registry has almost doubled within the last 10 years and exceeded 1500 entries in 2012. 8, 9 However, relapse is still a major cause of failure after alloHSCT for lymphoma, and in the absence of effective salvage options in this situation these patients have a poor outlook.
In patients with acute leukemias or CML, preliminary data suggest that a second alloHSCT (alloHSCT_2) might be a reasonable treatment strategy for patients with disease recurrence after a first alloHSCT (alloHSCT_1), especially if the interval between first transplant and relapse is not too short and disease control can be achieved before the second allogeneic transplant. [10] [11] [12] [13] [14] In contrast, information on alloHSCT_2 in patients with lymphoma is sparse. The purpose of the present registry study was to assess the outcome of second allogeneic transplants performed for lymphoma relapse after a alloHSCT_1. The results suggest that long-term lymphoma control can be achieved by alloHSCT_2 in a significant proportion of patients, with superior results in those patients who have a longer interval between alloHSCT_1 and alloHSCT_2 and who have chemosensitive disease at alloHSCT_2, thereby resembling experience obtained in patients with acute leukemia.
PATIENTS AND METHODS

Data source
EBMT is a voluntary organization comprising 4500 transplant centers mainly from Europe. Accreditation as a member center requires submission of minimal essential data (MED-A form) from all consecutive patients to a central registry in which patients may be identified by the diagnosis of underlying disease and type of transplant. Informed consent for transplantation and data collection was obtained locally according to regulations applicable at the time of transplantation. Since 1 January 2003, all transplant centers have been required to obtain written informed consent before data registration with the EBMT following the Helsinki Declaration 1975.
Study design
This was a registry-based retrospective multicenter study including patients aged ⩾ 18 years who underwent an alloHSCT_2 between 2000 and 2011 that was performed because of lymphoma relapse after an alloHSCT_1 and was reported to the EBMT. A minimum interval of 3 months between alloHSCT_1 and alloHSCT_2 was required as an additional measure to exclude nonrelapse-based second allotransplants. The main objectives were to assess the safety and efficacy of alloHSCT_2 using PFS and nonrelapse mortality (NRM) as readouts.
Baseline patient, disease and transplant data were collected from minimal essential data (MED-A form). Centers with potentially eligible patients were contacted to provide additional data, including salvage therapy after alloHSCT_1, high-dose regimen used and updated follow-up information. The full protocol of the study can be found in Supplementary Appendix (online only).
Definitions
For the purpose of this analysis, refractory and untreated relapse, stable disease and progressive disease were grouped together as chemorefractory disease. CR, PR and sensitive relapse were categorized as chemosensitive disease.
Statistical analysis
Statistical analysis was descriptive, and it used log-rank comparisons for univariate assessment of the impact of baseline characteristics on survival end points. Co-primary end points studied were OS and PFS after alloHSCT_2. OS was defined as the time from alloHSCT_2 to death from any cause, and PFS was defined as the time from alloHSCT_2 to relapse or progressive disease or death from any cause, whatever came first. Secondary end points were incidence of disease relapse or progression (RI) and NRM, and incidence of chronic GVHD. Progression was defined as any increase in the size of sites of disease, the development of new sites of disease or the recurrence of disease after alloHSCT_2. NRM was defined as death from any cause other than disease relapse or progression. The probabilities for OS and PFS were estimated from the time of alloHSCT_2 using the Kaplan-Meier product-limit estimate and were compared by the log-rank test in univariate analysis. Estimates of NRM and RI were calculated using cumulative incidence rates to accommodate competing risks and were compared by Gray's test. Multivariate analyses of OS and PFS were performed using Cox regression modeling stratified for variables not respecting the proportional hazard assumption. Multivariate analysis of RI and NRM were performed using Fine and Gray regression models. All P-values o0.05 were considered significant. Variables included in multivariate models were significant at the 0.2 level in univariate or unbalanced between the groups under study or known to have an impact on the outcome studied. All statistical analyses were performed using version R 2.15.3 (R Foundation for Statistical Computing, Vienna, Austria, http://www. R-project.org).
RESULTS
Patient characteristics
Altogether, 140 patients were identified in the database who met the eligibility criterion for this study. Underlying disease was Hodgkin lymphoma (HL) in 31%, follicular lymphoma in 16%, mantle cell lymphoma in 16%, diffuse large B-cell lymphoma in 14%, T-cell lymphoma (TCL) in 12% and other lymphomas in the remaining 11% of the patients. The median interval between alloHSCT_1 and alloHSCT_2 was 19 (range 3-116) months. Disease status at alloHSCT_2 was sensitive in 46%, refractory in 43% and unknown in 11% of the patients (Table 1) . Conditioning for alloHSCT_2 was chemotherapy-based in 74% and TBI-based in 26% of the 110 patients with detailed information available. Of the 29 patients with TBI-based conditioning, 13 were treated with myeloablative doses (⩾8 Gy). 15 Overall, conditioning intensity was considered as myeloablative in one-third of the patients. Conditioning details are described in Supplementary Table 1 .
Detailed information on salvage treatments for relapse after alloHSCT_1 was available for 47 patients. Of these, 10 patients (21%) received DLI, which was followed by MoAbs and/or chemotherapy in eight of them. Nineteen patients (40%) were treated with chemotherapy only and 13 (28%) with both chemotherapy and MoAbs. Additional radiotherapy was given to Abbreviations: HSCT = hematopoietic SCT; TT = thiotepa. 
of MoAbs in four patients (9%), whereas a single patient received radiotherapy only. OS, PFS, NRM and RI after alloHSCT_2 of the patient cohort with detailed treatment information available did not differ significantly from those of the patients without this information.
GVHD
Grade II-IV and III-IV acute GVHD, respectively, was reported in 40 and 16 patients (31% and 13%) of 124 patients with information available after alloHSCT_2. The cumulative incidence of chronic GVHD was 35% at 12 months and 45% at 24 months post second allogeneic transplant. In contrast, after alloHSCT_1, chronic GVHD was observed only in 16% of informative patients.
Outcome of alloHSCT_2
With a median observation time of surviving patients of 38 (interquartile range, (IQR) 22-82) months, 96 patients (70%) died. Cause of death was progressive lymphoma in 47 of these and NRM in the remainder, mainly owing to infections and/or GVHD. Deaths because of secondary malignancies were not reported. The cumulative incidences of NRM and relapse/progression 3 years post alloHSCT_2 were 23 and 58%, translating into 3-year probabilities for PFS and OS of 19% and 29%, respectively ( Figure 1 ).
Prognostic factors
By univariate comparisons, refractory or unknown disease status at alloHSCT_2, a shorter interval (⩽12 months) between alloHSCT_1 and alloHSCT_2 and the use of an unrelated donor for the second allograft significantly affected survival, whereas age, lymphoma subtype (HL vs TCL vs B-cell non-HL) and the use of a different donor in alloHSCT_2 than in alloHSCT_1 had no significant impact. The same results were observed for PFS, except that the adverse effect of an unrelated donor was not significant. Significant predictors for relapse and NRM could not be identified (Supplementary Table 2 ). Multivariate Cox modeling confirmed refractory disease at alloHSCT_2 and a short interval between the two allotransplants but not unrelated donor as unfavorable risk factors for OS and PFS (Table 2) . Patients who received their second allograft for chemosensitive disease 412 months after the first allograft had a 5-year PFS and OS of 25% and 35%, respectively (Figure 2) .
Although no significant survival differences emerged when lymphoma subsets were grouped as described above (HL vs TCL; HL vs B-cell non-HL), a more subtle categorization by single entities revealed that long-term progression-free survivors were virtually absent in patients with mantle cell lymphoma and diffuse large B-cell lymphoma, with zero and one patient remaining event-free beyond 3 years after alloHSCT_2. In contrast, PFS at 5 years after alloHSCT_2 for HL, TCL and indolent lymphoma was 20%, 27% and 31%, respectively (Figure 3 ).
DISCUSSION
Lymphoma recurrence after an allogeneic transplant is associated with a dismal prognosis. Two larger series from the US reported 3-year OS rates of 40% and 33%, respectively, measured from the time of relapse, with only few long-term survivors. 16, 17 Unlike these studies based on relapse as denominator, however, the present study based on second transplants as denominator cannot provide valid information on the impact of alloHSCT_2 or any other intervention on the natural course of lymphoma recurrence after alloHSCT_1. Instead, the purpose of this study was to evaluate the feasibility of alloHSCT_2 in lymphoma and to identify conditions in which it may be particularly promising or unsuccessful.
To this end, the present study provides first evidence that a second allotransplant can result in long-term remission in a substantial fraction of patients who have relapsed after a alloHSCT_1 for lymphoma. With a 3-year OS probability of 29%, survival resembles that reported for second allotransplants for relapsed myeloid malignancies, ranging from 21% after 2 years to 32% after 5 years. Second allogeneic transplantation for lymphoma relapse K Horstmann et al Importantly, the 3-year NRM of 23% observed here compares well with NRM figures observed in registry studies on first allotransplants in lymphoma, 2, [19] [20] [21] [22] [23] [24] [25] implying that a repeat allotransplant does not seem to be associated with an unacceptable increase in NRM.
Similar to leukemia, [10] [11] [12] [13] [14] 18 the most important risk factors adversely affecting OS after alloHSCT_2 for lymphoma were remission status at second transplant and interval between alloHSCT_1 and alloHSCT_2 (as a surrogate marker for remission duration after alloHSCT_1). In contrast, selecting a donor for alloHSCT_2 different from that used for alloHSCT_1 had no significant impact on OS, PFS or RI in the patient sample studied here. This finding is also in keeping with observations made in leukemia studies, 11, 12 with the exception that in the German Cooperative Transplant Study Group analysis a small group of second transplants from an alternative sibling donor yielded significantly better results than those achieved with repeat use of the first sibling or unrelated donor or an alternative unrelated donor. 12 Notably, although this subset analysis was limited by small numbers, patients with mantle cell lymphoma and diffuse large B-cell lymphoma did not benefit from a second alloHSCT, whereas long-term PFS after alloHSCT occurred in a substantial proportion of patients with HL, TCL and, in particular, indolent lymphoma. Although the 20-30% PFS plateaus observed seem to be inferior to 3-year PFS rates ranging from 25 to 60% in registry studies on first allotransplants in HL, TCL and follicular lymphoma, 19, 20, [25] [26] [27] this outcome is in line with circumstantial evidence suggesting that these three entities are more susceptible to GVL than aggressive B-cell lymphoma. 24, 28 In addition, the finding that in many patients chronic GVHD was absent after alloHSCT_1 but not after alloHSCT_2 is consistent with the conclusion that a second allotransplant might induce an effective allo-response in patients in whom it failed to appear after the first transplant, even if we were not able to show a direct correlation between chronic GVHD and disease control after alloHSCT_2.
In summary, the present study suggests that alloHSCT_2 is not associated with excess NRM, and it can result in long-term disease control in patients with lymphoma recurrence after alloHSCT_1, in particular in those whose relapse occurs late and is chemosensitive. Twenty to thirty percent of secondarily allografted patients with HL, TCL or indolent lymphoma live progression-free at 3 years post alloHSCT_2, with only very few events thereafter, suggesting effective immunotherapy being conferred with second allotransplantation in these GVL-sensitive entities. In contrast, a benefit of alloHSCT_2 for aggressive B-cell lymphoma remains to be shown. Similarly, the evaluation of the overall impact of alloHSCT_2 on the prognosis of patients with HSCT_1 failure requires additional (ideally comparative) studies.
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